查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984115

急性综合症检测市场：按产品类型、综合征检测组合、技术、应用和最终用户划分－2026-2032年全球市场预测

Acute Care Syndromic Testing Market by Product Type, Syndromic Panel, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，急性症候群检测市场价值将达到 74.4 亿美元，到 2026 年将成长至 84 亿美元，到 2032 年将达到 181.4 亿美元，年复合成长率为 13.58%。

主要市场统计数据
基准年 2025 74.4亿美元
预计年份：2026年 84亿美元
预测年份 2032 181.4亿美元
复合年增长率 (%) 13.58%

简要介绍急性症候群检测的模式转移：说明临床整合、诊断速度和系统弹性。

在技​​术进步、临床工作流程变革以及对诊断速度和准确性日益增长的期望的推动下，急性护理中的综合征检测领域正经历着快速且可持续的发展。能够同时检测多种病原体的综合征检测在急诊医学和医院环境中正变得越来越普遍，因为在这些环境中，时间紧迫的决策会对患者的预后产生重大影响。随着临床团队努力缩短诊断时间并减少对经验性治疗的依赖，能够与临床工作流程无缝整合的诊断平台正从概念验证验证阶段迈向实际应用阶段。

技术、监管和医疗保健服务方面的变革正在重塑综合征检测的途径，并加速医疗保健机构中照护现场诊断的普及。

一系列变革正在重新定义急诊护理环境中综合症检测的开发、实施和维护。高倍率检测、整合式检体到结果平台以及先进的资料管理功能等技术创新正在降低快速诊断的门槛。这些技术与改进的检测设计相辅相成，在保持分析灵敏度和特异性的同时，扩大了病原体的检测范围，从而使临床应用从传统的呼吸道疾病检测扩展到神经系统、消化器官系统和性行为感染感染等领域。

评估 2025 年美国关税调整对供应链、医疗设备采购、製造奖励和临床营运的多方面影响。

2025年美国关税政策的调整为参与综合症检测的製造商、经销商和医疗保健机构带来了新的挑战。由于进口成本上升和前置作业时间不不确定性增加，原本以即时库存管理为优化策略的供应链被迫重新评估其筹资策略。为此，许多医疗设备和试剂供应商加快了供应商网路的多元化，并探索区域性生产和组装方案，以降低进口价格波动带来的风险。

深入的細項分析揭示了急性护理环境中面板采用模式和采购决策如何受到面板类型、产品类型、最终用户、技术和应用的影响。

精准理解市场区隔动态对于掌握需求集中区域以及采购决策的变化至关重要。在考虑使用针对特定综合征的检测组合时，由于神经系统感染的严重性，中枢神经系统疾病（包括脑炎和脑膜炎亚型）的检测组合优先考虑高分析灵敏度和快速出结果。消化器官系统感染疾病检测组合（区分细菌、寄生虫和病毒病原体）需要强大的多重检测能力和检体通用性。呼吸系统疾病检测组合（分为细菌、复杂病原体和病毒病原体）必须在广泛的检测覆盖范围和处理能力之间取得平衡，以应对季节性需求高峰。性行为感染检测组合（针对披衣菌感染、淋病和疱疹）需要能够处理多种检体类型的高特异性检测方法。

影响综合征检测计画实施和支持的区域趋势和战略考虑因素，包括美洲、欧洲、中东和非洲以及亚太地区。

区域趋势对综合征检测项目的部署策略、监管协调和支援基础设施有显着影响。在美洲，扩大照护现场和与电子健康记录系统整合的奖励正在推动医院和门诊诊所的部署，而区域供应链中心和生产能力则支援快速补货。在欧洲、中东和非洲，不同的法规结构和报销环境需要差异化的商业化策略以及客製化的服务模式，以适应检查室整合和集中化的不同趋势。在亚太地区，产能的快速扩张、本地生产投资以及对公共卫生监测的高度重视正在加速高通量和分散式平台的部署。

竞争格局和公司层面的策略如何影响急性综合征检测生态系统中的创新、伙伴关係和商业化。

在综合征检测生态系统中，企业策略正沿着多个维度不断演进，包括平台差异化、耗材垂直整合以及与检查室网路和医疗保健系统的策略合作。製造商致力于提供端到端解决方案，以最大限度地减少工作量、降低故障点，并实现与实验室资讯系统和电子健康记录的无缝整合。同时，各公司也投资于能够支援持续收入的耗材产品组合，并致力于设计模组化设备，以确保客户不会受到设备过时的影响。

为产业领导者提供切实可行的策略建议，以优化供应链韧性、加速临床部署，并使经营模式与医疗保健优先事项保持一致。

寻求获得永续竞争优势的行业领导者应优先考虑一系列综合倡议，以协调技术、供应链、临床应用和商业模式。首先，投资于平台互通性和开放资料标准能够加速临床整合，并支援下游分析以展现价值。其次，在製定本地分销应急计划的同时，实现製造和物流合作伙伴的多元化，可以最大限度地减少贸易中断和海关程序波动对营运的影响。第三，透过真实世界数据 (REW) 研究和以管理为重点的试点项目，将临床证据的生成融入商业部署，可以加速技术应用，并加强与保险公司的对话。

采用综合调查方法，结合一手访谈、二手文献、资料检验和检验，确保严谨而实用的见解。

本报告所采用的分析方法结合了结构化的初步研究、全面的二手文献综述和严谨的资料三角验证，从而确保了结论的可靠性和可操作性。初步研究包括对临床实验室负责人、采购经理、医院管理人员和技术开发人员进行深入访谈，以了解实际运作和决策标准。二级资讯来源包括同行评审的临床研究、监管指南、技术白皮书和公开的产品文​​檔，用于阐明性能特征和检验标准。

为了支持综合征检测中的经营团队决策，我们整合了相关结论，提取了对临床护理、营运和产业策略的关键见解。

总之，在急诊护理中，综合征检测正从一项新兴功能转变为快速临床决策、感染控制和公共卫生监测的营运基础。科技的成熟、医疗服务模式的变革以及政策环境的演变正在推动其更广泛的应用，而供应炼和贸易趋势则凸显了韧性和多元化筹资策略的重要性。细分市场分析表明，不同应用领域的临床优先事项各不相同。神经系统急症需要快速且高灵敏度的检测，而呼吸系统疾病的激增则需要可扩展的检测能力和灵活的检测组合，这就需要采用个人化的采购和检验方法来满足这些需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：急性症候群检测市场：依产品类型划分

  • 装置
    • 工作檯面
    • 护理点
  • 试剂盒和试剂
    • 墨水匣
    • 多路復用检测套组
    • 试剂
  • 软体服务
    • 资料管理
    • 服务合约

第九章：急性症候群检测市场－依综合征和检测项目划分

  • 中枢神经系统
    • 脑炎
    • 脑膜炎
  • 消化器官系统
    • 细菌
    • 寄生虫
    • 病毒性的
  • 呼吸系统
    • 细菌
    • 合成的
    • 病毒性的
  • 性行为感染传染病
    • 披衣菌感染和淋病
    • 疱疹

第十章：急性症候群检测市场：依技术划分

  • 质谱分析
  • 微阵列
  • 多重PCR
  • NGS
  • QPCR

第十一章：急性症候群检测市场：依应用领域划分

  • 鑑别诊断
  • 流行病学
  • 集体爆发调查
  • 研究
  • 监视

第十二章：急性症候群检测市场：依最终用户划分

  • 学术研究机构
  • 医院
  • 公共卫生检测实验室
  • 标准检验组织

第十三章：急性症候群检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：急性症候群检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：急性症候群检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国急性症候群检测市场

第十七章：中国急性病症检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Applied BioCode, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • BIOHM Health LLC
  • bioMerieux SA
  • Curetis GmbH by OpGen, Inc
  • CVS Health
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Genetic Signatures Ltd.
  • Hologic Inc.
  • Luminex Corporation
  • Microbiologics, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market was valued at USD 7.44 billion in 2025 and is projected to grow to USD 8.40 billion in 2026, with a CAGR of 13.58%, reaching USD 18.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.44 billion
Estimated Year [2026] USD 8.40 billion
Forecast Year [2032] USD 18.14 billion
CAGR (%) 13.58%

A concise introduction to the shifting paradigm in acute care syndromic testing, highlighting clinical integration, diagnostic speed, and system resilience

The landscape of acute care syndromic testing is experiencing a rapid and sustained evolution driven by technological advances, shifting clinical workflows, and heightened expectations for diagnostic speed and precision. Syndromic testing, which enables simultaneous detection of multiple pathogen classes, is increasingly embedded into urgent care and hospital settings where time-sensitive decisions can materially affect patient outcomes. As clinical teams seek to shorten diagnostic windows and reduce empiric therapy reliance, diagnostic platforms that integrate seamlessly with care pathways are moving from proof-of-concept to operational necessity.

Moreover, the interplay between laboratory infrastructure and point-of-care capabilities is reshaping procurement priorities. Healthcare administrators are balancing the need for high-throughput centralized testing with decentralized solutions that deliver actionable results close to the bedside. In parallel, public health authorities and infection prevention teams are leveraging syndromic data to support surveillance and outbreak response, further emphasizing the role of diagnostics in broader population health strategies. Consequently, stakeholders across clinical, operational, and commercial functions must align around real-world performance, interoperability, and the ability to demonstrate clinical utility within constrained budgets.

Transformative technological, regulatory, and care-delivery shifts reshaping syndromic testing pathways and accelerating point-of-care diagnostics adoption across institutions

Transformative shifts are converging to redefine how syndromic testing is developed, adopted, and sustained in acute care settings. Technological innovations such as highly multiplexed assays, integrated sample-to-answer platforms, and advanced data management capabilities are lowering barriers to rapid diagnosis. These technologies are complemented by improvements in assay design that increase pathogen breadth while preserving analytical sensitivity and specificity, which in turn expands clinical use cases beyond traditional respiratory panels into neurological, gastrointestinal, and sexually transmitted infection applications.

Concurrently, care-delivery models are adapting; emergency departments, intensive care units, and outpatient urgent care centers are demanding faster turnarounds and simplified workflows that reduce dependency on specialized laboratory staff. Regulatory landscapes and reimbursement frameworks are also evolving, encouraging faster adoption when clinical value can be demonstrated through outcomes, antibiotic stewardship, and reduced length of stay. Finally, digital connectivity and analytics are enabling near-real-time aggregation of syndromic results, creating opportunities for improved institutional surveillance and cross-institutional public health signal detection. Taken together, these shifts are accelerating the translation of syndromic testing from niche diagnostic aid to an essential element of acute care management.

Assessing the multifaceted consequences of United States tariff adjustments in 2025 on supply chains, device sourcing, manufacturing incentives, and clinical operations

Adjustments to tariff policies in the United States during 2025 introduced renewed considerations for manufacturers, distributors, and healthcare providers involved with syndromic testing. Supply chains that had been optimized for just-in-time inventory were forced to re-evaluate sourcing strategies as import costs and lead-time uncertainty increased. In response, many device and reagent suppliers accelerated diversification of vendor networks and explored regional manufacturing and assembly options to mitigate exposure to import volatility.

Consequently, procurement teams in hospitals and reference laboratories instituted more stringent supplier risk assessments and prioritized long-term supply agreements that provided greater transparency around capacity and contingency planning. For platform manufacturers, the tariff environment prompted reassessment of pricing structures and total cost of ownership models that account for logistics, customs delays, and inventory carrying costs. Over time, these adjustments influenced product roadmaps and capital allocation decisions, encouraging investments in modular designs and interchangeable consumables that reduce dependency on single-source components.

Importantly, clinical operations experienced transitional friction as lead-time variability affected kit availability for high-demand panels. In response, laboratories expanded validation of alternative assays and intensified collaboration with clinical stakeholders to prioritize testing based on acuity and infection control imperatives. Through these adaptations, the sector demonstrated resilience, but the tariff-induced disruptions underscored the strategic importance of supply chain transparency, manufacturing agility, and proactive stakeholder communication.

Insightful segmentation analysis revealing how panels, product types, end users, technologies, and applications drive adoption patterns and procurement decisions in acute care

A nuanced understanding of segmentation dynamics is essential to appreciate where demand will concentrate and how procurement choices will evolve. When testing is considered by syndromic panel, the central nervous system category, with its encephalitis and meningitis subgroups, prioritizes high analytical sensitivity and rapid turnaround due to the critical nature of neurological infections; gastrointestinal panels that distinguish bacterial, parasitic, and viral etiologies demand robust multiplex capability and specimen versatility; respiratory panels categorized across bacterial, combined, and viral targets must balance breadth with throughput to serve seasonal surges; and sexually transmitted infection panels that profile chlamydia, gonorrhea, and herpes require assays optimized for diverse specimen types and high specificity.

From a product-type perspective, instruments-ranging from benchtop analyzers to point-of-care devices-drive capital planning and lab footprint decisions, while kits and reagents including cartridges, multiplex assay kits, and standalone reagents underpin recurring revenue and supply continuity considerations; software and services focused on data management and service contracts are increasingly decisive for long-term total cost and operational efficiency. End-user segmentation clarifies adoption pathways: academic research institutes prioritize assay flexibility and depth for translational work, hospitals require validated workflows and rapid clinical reporting, public health laboratories emphasize surveillance compatibility and high-throughput capacity, and reference laboratories focus on scale and assay multiplexing to serve broad client networks. Technology choices also shape strategy: options such as mass spectrometry, microarray, multiplex PCR, next-generation sequencing, and qPCR each present distinct trade-offs in throughput, breadth, and turn-around time. Finally, applications including differential diagnosis, epidemiology, outbreak investigation, research, and surveillance determine performance requirements and the degree of integration with clinical and public health information systems. Collectively, these segmentation axes inform procurement prioritization, validation strategies, and partnership models across stakeholders.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and support of syndromic testing programs

Regional dynamics materially influence deployment strategies, regulatory alignment, and support infrastructures for syndromic testing programs. In the Americas, incentives for point-of-care expansion and integrated electronic health record connectivity are shaping hospital and outpatient adoption, while regional supply chain hubs and manufacturing capacity support responsive replenishment. Across Europe, the Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement environments necessitate differentiated commercialization approaches, as well as tailored service models that account for variable laboratory consolidation and centralization trends. In the Asia-Pacific region, rapid capacity expansion, localized manufacturing investments, and strong public health surveillance priorities have accelerated adoption of both high-throughput and decentralized platforms.

These regional distinctions affect not only where technologies are adopted but how companies structure market entry and post-sale support. For instance, service contracts and local technical support are critical in regions with limited on-site technical expertise, whereas software interoperability and data-sharing standards are prioritized in systems with advanced digital health infrastructures. Moreover, procurement cycles and capital allocation differ across regions, influencing the pace of roll-out for new panels and platform upgrades. Understanding these geographic nuances enables planners to align distribution strategies, local partnerships, and training programs to regional expectations and operational realities.

Competitive landscape and company-level strategies shaping innovation, partnerships, and commercialization in the acute care syndromic testing ecosystem

Corporate strategies within the syndromic testing ecosystem are evolving along multiple vectors, including platform differentiation, vertical integration of consumables, and strategic partnerships with laboratory networks and health systems. Manufacturers focus on delivering end-to-end solutions that minimize hands-on time, reduce failure points, and provide seamless connectivity to laboratory information systems and electronic medical records. At the same time, firms are investing in consumable portfolios that support recurring revenue while designing instruments with modularity to protect customers against obsolescence.

Partnerships and consortium models are emerging as a way to accelerate market penetration and validate clinical utility across diverse care settings. Companies are increasingly collaborating with academic centers for clinical validation studies and with public health agencies to align reporting formats and surveillance use cases. Competitive dynamics are also influenced by service models, as rapid-response technical support and managed inventory programs become differentiators in procurement decisions. Overall, the marketplace favors organizations that can combine robust analytical performance with strong post-sale support, clear integration pathways, and flexible commercial terms that accommodate varied end-user needs.

Actionable strategic recommendations for industry leaders to optimize supply resilience, accelerate clinical adoption, and align commercial models with healthcare priorities

Industry leaders seeking to secure sustainable advantage should prioritize a set of integrated actions that address technology, supply chain, clinical adoption, and commercial alignment. First, investing in platform interoperability and open data standards will accelerate clinical integration and enable downstream analytics that demonstrate value. Second, diversifying manufacturing and logistics partners while building regional distribution contingencies will minimize the operational impact of trade disruptions and customs variability. Third, embedding clinical evidence generation into commercial rollouts-through real-world evidence studies and stewardship-focused pilots-will strengthen adoption and payer conversations.

Additionally, executives should consider modular pricing and service models that lower barriers to initial deployment and offer predictable total cost of ownership over time. Strengthening technical support and training programs will reduce implementation friction and improve clinician confidence in decentralized settings. Finally, cultivating strategic partnerships with public health institutions and reference networks can expand surveillance reach while creating shared validation pathways. By aligning product roadmaps, commercial models, and operational resilience initiatives, industry leaders can accelerate adoption while mitigating near-term market volatility.

Comprehensive research methodology integrating primary interviews, secondary literature, data triangulation, and validation to ensure rigorous and actionable insights

The analytical approach underpinning this report combined structured primary research, exhaustive secondary literature review, and rigorous data triangulation to ensure reliable and actionable findings. Primary research included in-depth interviews with clinical laboratory directors, procurement leads, hospital administrators, and technology developers to capture operational realities and decision-making criteria. Secondary sources comprised peer-reviewed clinical studies, regulatory guidance, technology white papers, and publicly available product documentation to contextualize performance characteristics and validation standards.

Data integration involved cross-checking interview insights against documented validation data and regulatory filings, enabling identification of consistent themes and divergence points. The methodology incorporated scenario analysis to explore supply chain sensitivities and adoption pathways under varying clinical and policy conditions. Quality assurance steps included multiple rounds of expert review and internal consistency checks to ensure that conclusions were robust and that limitations were transparently acknowledged. Where relevant, caveats around generalizability and regional applicability were stated to help readers interpret findings within their operational context.

Concluding synthesis that distills key implications for clinical care, operations, and industry strategy to inform executive decision-making in syndromic testing

In summary, syndromic testing in acute care is transitioning from emerging capability to an operational cornerstone of rapid clinical decision-making, infection control, and public health surveillance. Technological maturation, shifting care delivery models, and evolving policy contexts are collectively driving broader adoption, while supply chain and trade dynamics highlight the importance of resilience and diverse sourcing strategies. Segmentation analyses make clear that clinical priorities differ by application area-neurological emergencies require rapid, high-sensitivity assays while respiratory surges demand scalable throughput and flexible panel composition-necessitating tailored procurement and validation approaches.

Looking forward, stakeholders who combine technological interoperability, robust service models, and evidence-driven adoption programs will be best positioned to capture clinical and operational benefits. Strategic investments in localized manufacturing, flexible commercial offerings, and partnerships with public health and academic institutions will further enhance system preparedness. Ultimately, the organizations that align product design with real-world workflows and demonstrate measurable clinical impact will lead the transition toward more responsive, data-informed acute care diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Care Syndromic Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop
    • 8.1.2. Point Of Care
  • 8.2. Kits Reagents
    • 8.2.1. Cartridges
    • 8.2.2. Multiplex Assay Kits
    • 8.2.3. Reagents
  • 8.3. Software Services
    • 8.3.1. Data Management
    • 8.3.2. Service Contracts

9. Acute Care Syndromic Testing Market, by Syndromic Panel

  • 9.1. Central Nervous System
    • 9.1.1. Encephalitis
    • 9.1.2. Meningitis
  • 9.2. Gastrointestinal
    • 9.2.1. Bacterial
    • 9.2.2. Parasitic
    • 9.2.3. Viral
  • 9.3. Respiratory
    • 9.3.1. Bacterial
    • 9.3.2. Combined
    • 9.3.3. Viral
  • 9.4. Sexually Transmitted Infection
    • 9.4.1. Chlamydia Gonorrhea
    • 9.4.2. Herpes

10. Acute Care Syndromic Testing Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Multiplex Pcr
  • 10.4. Ngs
  • 10.5. Qpcr

11. Acute Care Syndromic Testing Market, by Application

  • 11.1. Differential Diagnosis
  • 11.2. Epidemiology
  • 11.3. Outbreak Investigation
  • 11.4. Research
  • 11.5. Surveillance

12. Acute Care Syndromic Testing Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Hospitals
  • 12.3. Public Health Laboratories
  • 12.4. Reference Laboratories

13. Acute Care Syndromic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Care Syndromic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Care Syndromic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Care Syndromic Testing Market

17. China Acute Care Syndromic Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Applied BioCode, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Biocartis NV
  • 18.10. BIOHM Health LLC
  • 18.11. bioMerieux SA
  • 18.12. Curetis GmbH b y OpGen, Inc
  • 18.13. CVS Health
  • 18.14. Danaher Corporation
  • 18.15. DiaSorin S.p.A
  • 18.16. Eurofins Scientific SE
  • 18.17. F. Hoffmann-La Roche Ltd
  • 18.18. Genetic Signatures Ltd.
  • 18.19. Hologic Inc.
  • 18.20. Luminex Corporation
  • 18.21. Microbiologics, Inc.
  • 18.22. Pfizer, Inc.
  • 18.23. QIAGEN N.V.
  • 18.24. QuantuMDx Group Ltd.
  • 18.25. Seegene Inc.
  • 18.26. Siemens Healthineers AG
  • 18.27. Sysmex Corporation
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. Werfen

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-203